Supporting data for Effects of Arsenic Trioxide on Lupus Nephritis –Results from Bioinformatics Analysis, Animal and in Vitro Studies

Lupus nephritis (LN) is a major complication of systemic lupus erythematosus (SLE) characterized by dysregulated B-cell activity and autoimmune kidney injury. Despite current therapies, treatment outcomes remain suboptimal, highlighting the unmet need for novel therapeutic strategies. Preclinical and clinical studies have reported the potential efficacy of ATO in SLE management, demonstrating its ability to modulate pathogenic B-cell responses and improve renal outcomes. However, the precise molecular mechanisms underlying ATO's immunomodulatory effects in LN remain incompletely understood. Results from this project have elucidated the therapeutic effects of oral ATO in LN and its putative pharmacological mechanisms. These data are clinically important for repurposing oral ATO for the management of LN and other autoimmune disorders.The dataset includes RT-qPCR data, expression public RNA-sequencing data, surface plasmon resonance data, animal related chemical index data, and flow analysis data.